New generation aromatase inhibitors in breast cancer: Weighing out potential costs and benefits

PharmacoEconomics

Volumn 17, Issue 2, 2000, Pages 121-132

  Higa, Gerald M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; GESTAGEN; LETROZOLE; LIAROZOLE; TAMOXIFEN; VOROZOLE;

ADRENALECTOMY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER HORMONE THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ESTROGEN SYNTHESIS; HYPOPHYSECTOMY; OVARIECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034016627     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017020-00002     Document Type: Article

References (95)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA A Cancer Journal for Clinicians 1999; 49 (1): 8-31
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 11: 104-7
3. Fisher B, Carbone PP, Econamou SG, et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975; 292: 117-22
4. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977; 1: 1174-6
5. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three auxiliary lymph nodes. Cancer Res 1985; 45: 4454-9
6. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16: 83-93
7. Henderson IC, Canellos GP. Cancer of the breast: the past decade. N Engl J Med 1980; 302: 17-30, 78-90
8. Peters WP, Rosner G, Vredenburgh J, et al. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol 1999; 18: A2
9. Bergh J, Scandanavian Breast Cancer Study Group. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstract]. Proc Am Soc Clin Oncol 1999; 18: A3
10. Stadtmauer EA, The Philadelphia Intergroup Study. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy [abstract]. Proc Am Soc Clin Oncol 1999; 18: A1
11. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: results of the French protocol PEGASE [abstract]. Proc Am Soc Clin Oncol 1999; 18: A161
12. Jensen EV, Block GE, Smith S, et al. Estrogen receptor and breast cancer response to adrenelectomy. Natl Cancer Inst Monogr 1971; 34: 55-70
13. Desombre ER, Carbone PP, Jensen EV, et al. Steroid receptors in breast cancer [special report]. N Engl J Med 1979; 301: 1011-2
14. Tumor Marker Guideline Panel of the American Society for Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77
15. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 reurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15
16. Mouridsen H, Palshof T. Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978; 5: 131-41
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 451-66
18. Lippman M, Dickson R. Growth regulation of normal and malignant breast epithelium. In: Bland KI, Copeland EM, editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia (PA): Saunders, 1991: 363-94
19. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-12
20. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28
21. Thompson EA, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatisation of androstenedione. J Biol Chem 1974; 249: 5364-72
22. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990; 33: 2933-42
23. McNatty KP, Baird DT, Bolton A, et al. Concentrations of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. J Endocrinol 1976; 71: 77-85
24. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207-14
25. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II: correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38: 476-9
26. Ryan KJ. Biological aromatization of steroids. J Biol Chem 1959; 234: 268-72
27. Siiteri PK. Review of studies on estrogen biosynthesis in the human. Cancer Res 1982; 42: 3269S-73S
28. Brodie A, Inkster S. Aromatase in the human testis. J Steroid Biochem Mol Biol 1993; 44: 549-55
29. Naftolin F, Ryan KJ, Petro Z. Aromatization of androstenedione. J Clin Endocrinol Metab 1970; 33: 368-70
30. Miller WR, Mullen P. Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 1993; 44: 597-604
31. Bulun SE, Simpson ER. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 1994; 30: 19-29
32. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 1991; 39: 783-90
33. Durgam VR, Tekmal RR. The nature and expression of int-5, a novel MMTV integration locus gene in carcinogen-induced tumors. Cancer Lett 1994; 87: 179-86
34. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997; 94 (20): 10937-42
35. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57 (24): 5493-7
36. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 1988; 48: 246-53
37. Spicer DV, Pike MC. Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat 1993; 28: 179-93
38. Reid SE, Murthy MS, Kaufman M, et al. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996; 83: 1037-46
39. Lupulescu A. Estrogen use and cancer incidence: a review. Cancer Invest 1995; 13: 287-95
40. Segaloff A. Hormones and mammary carcinogenesis. In: McGuire WL, editor. Advances in research and treatment, experimental biology. New York (NY): Plenum Press, 1978: 1-22
41. Kirschner MA. The role of hormones in the development of human breast cancer. In: McGuire WL, editor. Breast cancer 3: advances in research and treatment, current topics. New York (NY): Plenum Press, 1979: 199-226
42. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291-6
43. Toniolo PG, Levita M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-7
44. Lippman ME, Dickson RB. Growth control of normal and malignant breast epithelium. Prog Clin Biol Res 1990; 354: 147-78
45. Lippman ME, Bolan G. Oestrogen responsive breast cancer in long-term tissue culture. Nature 1975; 256: 592-3
46. Bates SE, Davidson NE, Valverius EM, et al. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988; 2: 543-5
47. Prall OWJ, Sarcevic B, Musgrove EA, et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272: 10882-94
48. Kandouz M, Siromachkova M, Jacob D, et al. Antagonism between estradiol and progestin on bcl-2 expression in breast-cancer cells. Int J Cancer 1996; 68: 120-5
49. Veronesi U, Pizzocaro G, Rossi A. Oophorectomy for advanced carcinoma of the breast. Surg Gynecol Obst 1975; 141: 569-70
50. Legha SS. Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988; 109: 219-28
51. Ward HWC, Arthur K, Banks AJ, et al. Anti-oestrogen therapy for breast cancer-a report on 300 patients treated with tamoxifen. Clin Oncol 1978; 4: 11-7
52. McInerney EM, Tsai MJ, O'Malley BW, et al. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci U S A 1996; 93: 10069-73
53. Kelloff GJ, Lubet RA, Fay JR, et al. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomark Prev 1997; 6: 267-82
54. Kaufman RJ. Advanced breast cancer-additive hormonal therapy. Cancer 1981; 47: 2398-403
55. Manni A, Trujillo JE, Marshall JS, et al. Anti-hormone treatment of stage IV breast cancer. Cancer 1979; 43: 444-50
56. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978; 38: 4289-91
57. Leitzel K, Teramoto Y, Konrad K, et al. Elevated c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-35
58. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 2518-25
59. Elledge R, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 1998; 4: 7-12
60. Soubeyran I, Quenel N, Coindre JM, et al. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in postmenopausal breast cancer. Br J Cancer 1996; 74: 1120-5
61. Bonadonna G, Brusamolino E, Valaguasa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 297: 405-10
62. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977; I: 1174-6
63. Early Breast Cancer Trialists' Collaborative Group. The effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319: 1681-92
64. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-9
65. Swedish Breast Cancer Co-operative Group. Randomised trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-9
66. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 1989; 320: 479-84
67. Ingle JN, Krook JE, Green SJ, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986; 4: 178-85
68. Buchanan RB, Blamey RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 1986; 4: 1326-30
69. Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer: the German Zoladex Trial Group. J Clin Oncol 1989; 7: 1113-9
70. Patterson JS. Nolvadex (tamoxifen) as an anticancer agent in humans. In: Sutherland RL, Jordan VC, editors. Non-steroidal antiestrogens: molecular pharmacology and antitumor activity. Sydney: Academic, 1981: 453-71
71. Thijssen JHH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989; 25: 1953-9
72. Diab SG, Castles CG, Fuqua SAW. Role of altered estrogen receptors in breast cancer. In: Vedeckis WV, editor. Hormones and cancer. Boston (MA): Birkhauser, 1996: 261-81
73. Cocconi G. First generation aromatase inhibitors: aminoglutethimide and testolactone. Breast Cancer Res Treat 1994; 30: 57-80
74. Johnston SR, Saccani-Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331-8
75. Encarnacion CA, Ciocca DR, McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237-46
76. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 1993; 26: 119-30
77. Fuqua SAW, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem 1993; 17G: 194-7
78. Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23 Suppl. 9: 10-20
79. Harper-Wynne C, Coombes RC. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 1999; 35: 744-6
80. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30: 311-4
81. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23: 1189-96
82. Kang Y, Cortina R, Perry RR. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 1996; 88: 279-84
83. Gagiardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993; 53: 533-83
84. Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-83
85. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenupausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404-12
86. Buzdar AV, Jones SE, Plourde P, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1996; 79: 730-9
87. Buzdar A, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer 1996; 77: 2503-13
88. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61
89. Goss PE, Winer EP, Tannock IF, et al. Randomised phase III trial comparing the new potent and selective third-generation aromatase inhibnitor vorozole with megesterol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 1999; 17: 52-63
90. Buzdar AU, Jonat W, Howell A, Arimidex Study Group, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83: 1142-52
91. Allred DC, O'Connell P, Fuqua SAW. Biomarkers in early breast neoplasia. J Cell Biochem 1993; 17G: 125-31
92. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl Cancer Inst 1998; 90 (18): 1371-88
93. Wright T. Anastrozole cost effective in advanced breast cancer. PharmacoEcon Outcomes News 1998; 147: 3-4
94. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721-8
95. Gershanovich M, Chaudri HA, Campos B, et al. Letrozole, a new oral aromastase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9: 639-45